| 摘要 |
The present disclosure provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the disclosure bind human PRLR with high affinity. In certain embodiments, the disclosure includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the disclosure includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the disclosure may be fully human antibodies. The disclosure includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the disclosure are useful for the treatment of various cancers as well as other PRLR-related disorders. The present disclosure also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent. |
